EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Exclusion of Women from Phase I Trials: Perspectives from Investigators and Research Oversight Officials

Margaret Waltz, Anne Drapkin Lyerly, Jill A Fisher

Ethics & Human Research · 2023-11 · 45 (6) · 19-30

DOI: 10.1002/eahr.500170 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Ethics & Human Research, online erschienen am 21.11.2023. Verfasst von Margaret Waltz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research scientist at the Center for Bioethics and in the Department of Social Medicine at the University of North Carolina at Chapel Hill. Hauptthemen laut MEDLINE: Research Personnel, Fetus. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past 30 years, progress has been made in increasing women's representation in clinical research. However, women continue to be underrepresented in phase I clinical trials—those trials that test the safety and tolerability of investigational drugs, often on healthy individuals. As sex‐based differences in adverse drug reactions are often linked to drug dose, pivotal safety information in phase I trials is often insufficiently—and inequitably—captured for females. Yet there has been little attention to how clinical investigators and those charged with overseeing the ethical conduct of these trials perceive the barriers to women's inclusion in phase I trials. To address this gap, we report on 22 interviews with U.S. phase I investigators and institutional review board (IRB) members. Our findings indicate that although these investigators and IRB members acknowledged the importance of including women in clinical trials, they justified women's exclusion from phase I trials by citing the need to manage their reproductive potential. In particular, we identified four key themes that informants used to warrant women's exclusion from phase I trials: the structure of the drug‐development system itself, fears about risks to potential fetuses, distrust of women to prevent pregnancy, and concerns about risks and burdens to institutions from resulting pregnancies. We argue that these rationales reflect structural and cultural barriers to women's inclusion in clinical research that ultimately fail to respect female research participants as persons, highlighting the need for broad‐based solutions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research PersonnelFetusPregnancyFemaleHumans

Stichwörter der Autor:innen

androcentrisminclusionphase I clinical trialsrespect for personsriskwomen

Autor:innen und Institutionen

  • Research scientist at the Center for Bioethics and in the Department of Social Medicine at the University of North Carolina at Chapel Hill.
  • Professor of social medicine at the Center for Bioethics and in the Department of Social Medicine at the University of North Carolina at Chapel Hill.

Förderung

  • NIAID NIH HHS
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences
  • Office of Research on Women's Health
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Waltz, M., Lyerly, A. D., & Fisher, J. A. (2023). Exclusion of Women from Phase I Trials: Perspectives from Investigators and Research Oversight Officials. Ethics & Human Research, 45(6), 19-30. https://doi.org/10.1002/eahr.500170

Vancouver

Waltz M, Lyerly AD, Fisher JA. Exclusion of Women from Phase I Trials: Perspectives from Investigators and Research Oversight Officials. Ethics & Human Research. 2023;45(6):19-30. doi:10.1002/eahr.500170

BibTeX
@article{Waltz2023,
  author = {Waltz, Margaret and Lyerly, Anne Drapkin and Fisher, Jill A},
  title = {Exclusion of Women from Phase I Trials: Perspectives from Investigators and Research Oversight Officials},
  journal = {Ethics & Human Research},
  year = {2023},
  volume = {45},
  number = {6},
  pages = {19--30},
  doi = {10.1002/eahr.500170}
}
Kostenlos starten →